Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant

Sarah L. Sammons; Keith W. Pratz; B. Douglas Smith; Judith E. Karp; Ashkan Emadi

doi:10.1002/ajh.23782

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant

Sarah L. Sammons, Keith W. Pratz, B. Douglas Smith, Judith E. Karp, Ashkan Emadi

School of Medicine

Research output: Contribution to journal › Letter › peer-review

30 Scopus citations

Original language	English (US)
Pages (from-to)	936-938
Number of pages	3
Journal	American journal of hematology
Volume	89
Issue number	9
DOIs	https://doi.org/10.1002/ajh.23782
State	Published - Sep 2014

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.23782

Cite this

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. / Sammons, Sarah L.; Pratz, Keith W.; Smith, B. Douglas et al.
In: American journal of hematology, Vol. 89, No. 9, 09.2014, p. 936-938.

Research output: Contribution to journal › Letter › peer-review

@article{df56bbe678b8431eae6db5f4fecfb494,

title = "Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant",

author = "Sammons, {Sarah L.} and Pratz, {Keith W.} and Smith, {B. Douglas} and Karp, {Judith E.} and Ashkan Emadi",

year = "2014",

month = sep,

doi = "10.1002/ajh.23782",

language = "English (US)",

volume = "89",

pages = "936--938",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant

AU - Sammons, Sarah L.

AU - Pratz, Keith W.

AU - Smith, B. Douglas

AU - Karp, Judith E.

AU - Emadi, Ashkan

PY - 2014/9

Y1 - 2014/9

UR - http://www.scopus.com/inward/record.url?scp=84906077953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906077953&partnerID=8YFLogxK

U2 - 10.1002/ajh.23782

DO - 10.1002/ajh.23782

M3 - Letter

C2 - 24898801

AN - SCOPUS:84906077953

SN - 0361-8609

VL - 89

SP - 936

EP - 938

JO - American journal of hematology

JF - American journal of hematology

IS - 9

ER -

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this